These differences may partially be explained by differences in methodology; the prevalence of anti-NXP2 in our cohort was similar to other adult myositis cohorts screened by IPP [17,36,37], but was significantly lower than the US cohort assayed by in-vitro IPP [32]. This evidence concerns the gene MORC3 and myositis disease.